⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGM

PVLA

Palvella Therapeutics, Inc.

Healthcare · Biotechnology

151.34USD

-0.9400 (-0.62%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.
Fiscal Year End12/2025
Last Quarter End06/2026 Q2
Current/T12M(USD)
1)

Issue Data

Last PxUSD / 151.34
P/E—
Dvd Ind Yld—
P/B10.12
P/S1,622.9
Curr EV/T12M EBITDA573.4
Mkt Cap (USD)2.2B
Curr EV (USD)2.0B
2)

Per Share Data

EPS T12M-4.88
DPS—
Bk Val Per Sh15.07
Rev/Sh0.09
Cash/Sh17.39
Curr Shares Out14.4M
FCF/Sh1.05
3)

Cash Flow Analysis

P/CF-60.1
Curr P/FCF146.1
CF/NI0.6
Dvd P/O0.0%
Cash Gen/Cash Reqd—
Csh Dvd Cov—
CFO/Sales-2700.7%
Eff Interest Rate0.8%
4)

Growth Potential

Dil EPS 1Y Gr-136.9%
Cap 1Y Gr-55.3%
BPS 1Y Gr-55.8%
R&D To Sales2622.5%
Retention Rate100.0%
Rev 1Y Gr65.3%
FCF 1Y Gr77.2%
Assets 1Y Gr-32.5%
5)

Profitability

EBITDA0.0B
EBIT-0.1B
Operating Margin-4270.8%
Pretax Margin-4563.3%
Net Margin-4563.3%
ROA-37.7%
ROE-46.6%
ROC-24.1%
Asset Turnover0.01
6)

Structure

Current Ratio21.18
Quick Ratio21.01
Debt/Assets8.9%
Debt/Com Eq10.4%
Net Debt/EBITDA-48.17
Tot Debt/Capital9.5%
Gross Margin0.0%
EBIT/Int Exp-319.0

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.